LRMR - Larimar Therapeutics, Inc. Stock Price, Fair Value and News
7.43USD-0.44 (-5.59%)Market Closed
Latest Insider Trading transactions for LRMR
| Datesorted ascending | Name | Buy/Sell | $ Value | # Shares | Avg. Price | Title |
|---|---|---|---|---|---|---|
| 2024-02-16 | Premium | bought | Premium | Premium | Premium | - |
| 2024-02-16 | Premium | bought | Premium | Premium | Premium | - |
| 2024-02-14 | Premium | bought | Premium | Premium | Premium | - |
| 2024-01-17 | Premium | acquired | Premium | Premium | Premium | Chief Development Officer |
| 2024-01-17 | Premium | acquired | Premium | Premium | Premium | Chief Medical Officer |
| 2024-01-17 | Premium | acquired | Premium | Premium | Premium | President and CEO |
| 2024-01-17 | Premium | acquired | Premium | Premium | Premium | Chief Financial Officer |
| 2023-12-07 | Premium | bought | Premium | Premium | Premium | Chief Development Officer |
| 2023-05-17 | Premium | bought | Premium | Premium | Premium | President and CEO |
| 2023-05-17 | Premium | bought | Premium | Premium | Premium | - |
| 2023-05-17 | Premium | bought | Premium | Premium | Premium | Chief Financial Officer |
| 2023-01-31 | Premium | acquired | Premium | Premium | Premium | President and CEO |
| 2023-01-31 | Premium | acquired | Premium | Premium | Premium | Chief Financial Officer |
| 2022-09-16 | Premium | bought | Premium | Premium | Premium | - |
| 2022-09-16 | Premium | bought | Premium | Premium | Premium | - |
| 2022-09-16 | Premium | bought | Premium | Premium | Premium | President and CEO |
| 2022-09-16 | Premium | bought | Premium | Premium | Premium | Chief Financial Officer |
| 2021-06-30 | Premium | bought | Premium | Premium | Premium | - |
| 2021-06-30 | Premium | bought | Premium | Premium | Premium | - |
| 2021-06-30 | Premium | bought | Premium | Premium | Premium | - |
| 2021-06-30 | Premium | bought | Premium | Premium | Premium | - |